iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Targeted therapy attacks a specific cancer-associated protein, gene change, or growth signal. Immunotherapy uses or changes immune activity so the body can recognize and attack cancer. The labels are broad: some targeted treatments recruit immune cells, and different immunotherapies work in very different ways. A biomarker can make a treatment worth considering, but it cannot guarantee that treatment will work or be safer. The appropriate choice depends on the exact cancer, test results, prior treatment, overall health, and evidence for the particular medicine.
This is general education, not an individualized treatment recommendation. Decisions should be made with the oncology team treating the specific cancer.
What is the core difference?
Targeted therapy is designed around a feature that helps cancer cells grow, divide, survive, or spread. The drug may block that feature directly or interfere with the signal it sends. Immunotherapy is designed around the immune system: it may remove immune “brakes,” stimulate immune cells, supply engineered cells, or otherwise change immune activity so cancer is attacked.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
That distinction describes the primary intent, not an absolute dividing line. A monoclonal antibody used as targeted therapy can mark a cancer cell for immune destruction. Conversely, an immunotherapy can be selected using a tumor feature that predicts whether immune activation is plausible. The medicine’s name, mechanism, approved use, and evidence matter more than the category label.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
| Question | Targeted therapy | Immunotherapy |
|---|---|---|
| Primary aim | Interrupt a defined cancer-related target or signaling pathway. | Activate, release, redirect, or supply immune activity against cancer. |
| Typical selection clue | A molecular change or protein target found in the tumor or cancer cells. | A feature suggesting the immune system may recognize or respond to the cancer, plus the cancer type and clinical setting. |
| How it can fail | The target is absent, inaccessible, or altered so the drug no longer works. | The immune response is insufficient, the tumor evades it, or resistance develops. |
| Main safety concern | Effects on normal cells that share the target or pathway. | Immune activity directed at healthy tissues. |
Neither column is automatically more effective or gentler. Results differ by medicine, cancer subtype, dose, treatment combination, and patient.
How targeted therapy works
Small-molecule drugs
Small-molecule medicines can enter cells and bind internal proteins, including enzymes that transmit growth signals. Blocking a driver signal can slow cell division or trigger cancer-cell death. The National Cancer Institute describes targeted therapy as treatment aimed at proteins controlling cancer-cell growth, division, and spread.
Monoclonal antibodies
Monoclonal antibodies circulate outside cells and attach to selected proteins on the cancer-cell surface or in the surrounding environment. Depending on the drug, binding can block a growth message, flag the cell for immune destruction, or deliver a toxic payload. Because immune cells may participate in the killing process, it is inaccurate to say targeted therapy never involves immunity.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Why the target matters
A drug can only act as intended if the cancer has the relevant target and the target remains important to the cancer. Cancers from the same organ can have different molecular drivers, while a target may appear in several cancer types. Testing and the treatment’s approved evidence determine whether the mechanism is relevant.
What treatment delivery can look like
Some targeted medicines are tablets or capsules taken on a schedule, while others are given by infusion or injection. The route does not define the category. A tablet still requires laboratory checks, review of other medicines, and instructions about missed doses or food interactions; an infusion may require observation for reactions. The oncology team will explain the exact schedule, whether doses are adjusted for organ function, and what to do if a dose is delayed or vomited.
How immunotherapy works
Checkpoint inhibitors
Some tumors exploit checkpoint signals that restrain T cells. Checkpoint inhibitors block those signals, allowing an existing immune response to remain active or become stronger. The result depends on whether immune cells can recognize the tumor and whether the tumor has other ways to evade attack.
Cell-based approaches
Cell-based immunotherapies use immune cells that are collected, selected or engineered, and returned to the patient, or otherwise provide immune cells with new cancer-recognition capabilities. Their preparation, eligibility requirements, monitoring, and risks are specific to the individual treatment.
Free tools Windows power users keep installed
One-click scans. No signup required.
Other immune-modulating strategies
Immunotherapy is a family rather than one drug class. Treatments can stimulate immune signaling, provide immune proteins, alter the tumor environment, or combine immune approaches with chemotherapy, radiation, surgery, or targeted medicines. Side effects and expected benefits therefore cannot be inferred from the word “immunotherapy” alone.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Why two immunotherapies may feel very different
A checkpoint inhibitor given periodically in an infusion has different logistics from a cell-based treatment that requires collection, manufacturing, and a planned return to the treatment center. Eligibility can depend on blood counts, organ function, infection status, previous therapies, or other health factors. Ask for the product-specific plan rather than assuming that the experience or precautions of one immunotherapy apply to another.
Does biomarker testing determine which treatment you get?
It can help, but it does not make the decision by itself. The National Cancer Institute states: “Some cancer treatments, including targeted therapies and immunotherapies, may only work for people whose cancers have certain biomarkers.” A biomarker is a measurable gene change, protein, cell feature, or other characteristic of a tumor or the patient that may provide treatment information.
Testing for a targeted-treatment marker
One NCI example is testing for an EGFR gene change to determine whether an EGFR inhibitor may be an option. Other tests look for a protein or fusion involving a treatment target. The report may identify an approved option, a possible off-label use, or a clinical trial. It may also show that a particular drug is unlikely to help.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsTesting for an immunotherapy-related feature
Tests can assess tumor features that inform some immunotherapy decisions, such as characteristics associated with checkpoint-inhibitor sensitivity. A result is interpreted alongside the cancer type, stage, prior treatment, and the evidence for the exact immunotherapy. A marker that is useful in one cancer or treatment setting may not have the same meaning in another.
How samples are obtained
Testing commonly uses tumor tissue removed during a biopsy or surgery. In some circumstances, a liquid biopsy analyzes tumor-derived material in blood. A blood-based test may be useful when tissue is difficult to obtain, but the oncology team must judge whether the result is adequate for the decision. A negative or inconclusive result can reflect the limits of the sample or assay rather than proof that no relevant feature exists.
How testing is handled step by step
- The team confirms the diagnosis and identifies the tissue or blood sample that can be tested.
- The laboratory analyzes one or more genes, proteins, or other tumor characteristics. A single-marker test and a broader panel may answer different questions.
- The oncologist checks whether the finding has an approved treatment, supports an off-label option, or fits a clinical trial.
- The result is weighed against stage, prior treatment, symptoms, organ function, other medicines, and the patient’s goals.
- If the cancer changes, the team may discuss another sample or a liquid biopsy because the biology and relevant biomarkers can change.
What a result can and cannot tell you
- A matching biomarker can make a treatment an option; it is not a prescription.
- It does not guarantee tumor shrinkage, longer survival, or tolerable side effects.
- Biomarkers can change as cancer evolves or after treatment.
- Tests do not provide useful guidance for every person or every medicine.
- The cancer team must combine the result with diagnosis, treatment history, health status, and available evidence.
- A result that is technically positive may still have uncertain significance if the treatment has not been studied in that cancer or setting.
How side effects differ
Both categories can cause serious problems, and neither is inherently safer. The timing and warning symptoms depend on the actual drug, dose, combinations, and the patient’s health. The prescribing team’s medication guide is the authority for treatment-specific instructions.
Potential effects of targeted therapy
Because targeted drugs act on proteins or pathways that may also exist in healthy cells, normal tissues can be affected. Across different targeted medicines, reported problems can include skin or nail changes, diarrhea, fatigue, high blood pressure, liver or other organ effects, and reactions related to the particular target. A side effect that is common with one targeted drug may be unusual with another.
Potential effects of immunotherapy
NCI explains that immune-related side effects occur when an activated immune system attacks healthy tissue. Inflammation can involve the skin, bowel, lungs, liver, kidneys, nerves, joints, heart, hormone-producing glands, or other organs. Symptoms may arise during treatment or after an infusion, and some can persist after treatment ends. Early reporting matters because suppressing the immune reaction may prevent a mild problem from becoming severe.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Monitoring and when to call
The oncology team may use examinations, blood tests, imaging, symptom checks, and organ-specific tests. Ask in advance which symptoms require a same-day call, which require emergency care, and who answers after hours. Do not self-treat a new fever, breathing difficulty, severe diarrhea, confusion, jaundice, chest pain, or rapidly worsening symptom without contacting the care team or emergency services as instructed.
Preparing for safer treatment
Before the first dose, provide a complete list of prescription drugs, over-the-counter medicines, vitamins, and supplements. Tell the team about autoimmune disease, an organ or stem-cell transplant, chronic infections, prior immune-related reactions, liver or kidney problems, and pregnancy or breastfeeding plans. These factors do not automatically rule out a treatment, but they can change monitoring, timing, or the balance of risks and benefits. Keep the treatment name and the after-hours contact number available at home.
Response, resistance, and what happens if treatment stops working
Targeted-therapy resistance
If the intended target is absent, the cancer may not respond from the start. A tumor that initially responds can acquire additional changes, activate a bypass pathway, alter the target, or otherwise become resistant. Progression may prompt repeat molecular testing, a different targeted drug, a combination, chemotherapy, radiation, surgery, or a clinical trial, depending on the cancer.
Recommended Free Tools
Immunotherapy resistance or nonresponse
Some tumors do not generate an effective immune response, while others exclude immune cells, suppress them, or evolve to evade recognition. A cancer can also progress after an initial response. The team may confirm progression with imaging and clinical assessment, consider whether inflammation is confusing the scan, and then weigh another regimen or trial. There is no universal response-rate winner between the two categories across all cancers.
How benefit is assessed
Assessment can include scans, physical findings, laboratory results, tumor markers when validated for that cancer, symptom changes, and the ability to continue treatment. The schedule and definition of response are treatment- and disease-specific. Ask what result would count as benefit, stable disease, unacceptable toxicity, or progression before starting.
Why treatment may be paused or changed
A pause, dose reduction, or switch does not always mean the cancer has progressed. Clinicians may hold treatment to investigate a symptom, allow an organ to recover, manage an interaction, or confirm a scan. Conversely, treatment may be changed even when a scan is stable if toxicity is unacceptable or a better-supported option becomes available. Ask what finding would trigger each possible change and whether the goal is cancer control, symptom relief, or both.
How clinicians choose between the categories
The decision is an individualized balance rather than a contest between labels. Important considerations include:
- Cancer identity: organ of origin, subtype, stage, spread pattern, and molecular features.
- Evidence for the exact treatment: whether it is approved or being considered in a trial, and what outcomes were observed in a comparable setting.
- Prior treatment: previous drugs, radiation, surgery, responses, resistance mutations, and lingering toxicities.
- Patient context: organ function, autoimmune disease, transplant history, infections, other medicines, pregnancy considerations, ability to attend monitoring, and personal goals.
- Practical factors: infusion versus tablets, dosing schedule, laboratory and imaging requirements, access to urgent advice, and clinical-trial availability.
Two people with the same broad cancer type may reasonably receive different approaches because their tumors and health histories differ. A biomarker result narrows possibilities; it does not replace clinical judgment.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Combination treatment and sequencing
Targeted therapy and immunotherapy are sometimes used together or in sequence, along with chemotherapy, radiation, or surgery. Combining mechanisms may be intended to overcome resistance or address different cancer populations, but it can also add toxicities, monitoring, and uncertainty. The team should explain why a combination is being proposed, which component is expected to provide which benefit, and how side effects will be distinguished and managed.
Questions to ask before starting treatment
- What is the exact name of the treatment, and what does it target or change in my cancer?
- Which biomarker results support or rule out this option? How reliable is the test, and could the result change later?
- Is this use approved for my diagnosis, an off-label option, or a clinical-trial treatment?
- What benefits were seen in people with a similar cancer and treatment history?
- Which side effects are expected, which are emergencies, and whom do I contact after hours?
- What examinations, blood tests, scans, or other monitoring will I need, and how often?
- How will you determine whether the treatment is working, and when will we reassess?
- What alternatives could be considered if the cancer does not respond or later progresses?
- Could my other medicines, autoimmune conditions, organ problems, or pregnancy plans change the recommendation?
- How is the treatment given, how long does each visit take, and what should I do about a missed dose or delayed appointment?
Common misconceptions
“Targeted” means harmless
Targeted action improves biological precision, not immunity from toxicity. Healthy cells can share the target, and blocking a pathway can disturb normal organ function.
“Immunotherapy” is one treatment
Checkpoint inhibitors, cell-based treatments, immune stimulants, and other approaches have different mechanisms, eligibility rules, and adverse effects. The product-specific information is essential.
A positive biomarker guarantees success
A biomarker indicates that a treatment may be relevant. Cancer biology, drug exposure, resistance, and patient health still determine whether benefit occurs.
Only immunotherapy can involve the immune system
Some targeted antibodies recruit immune mechanisms, and targeted treatments may be combined with immunotherapy. Describe what the actual medicine does rather than relying on a label.
A negative test rules out every option
A negative or inadequate result may rule out one biomarker-dependent treatment, but it does not necessarily rule out all targeted drugs, immunotherapies, standard treatments, or trials. The meaning depends on the assay, the sample, and the medicine under consideration.
Bottom line for patients and caregivers
Targeted therapy focuses on a cancer-associated target or signal; immunotherapy focuses on changing immune activity against cancer. Biomarker testing can guide either kind of treatment, but a result is not a guarantee. The meaningful comparison is between the specific medicines being considered: their mechanism, evidence for the cancer, testing requirements, monitoring plan, side effects, and options if resistance develops. An oncology team can apply those details to the patient’s diagnosis and goals.
Frequently Asked Questions
Is targeted therapy better than immunotherapy?
Neither category is universally better. Benefit depends on the specific cancer, biomarker findings, treatment evidence, prior therapies, health conditions, and the exact medicine.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Do I need biomarker testing before immunotherapy?
Testing may help identify whether some immunotherapies are relevant, but requirements differ by medicine and cancer. Your oncology team can explain which test, if any, is useful and how much it can predict.
Can targeted therapy and immunotherapy be given together?
They can be combined or used in sequence in some settings. The rationale, evidence, dosing, and added risks are specific to the regimen.
How long does it take to know whether treatment is working?
There is no single timetable. Teams use treatment-specific scans, examinations, laboratory results, symptoms, and sometimes validated tumor markers, then reassess according to the cancer and regimen.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Can a biomarker change after treatment starts?
Yes. Cancer can evolve, and treatment can select resistant cells. If the cancer progresses, the team may discuss repeat tissue or liquid-biopsy testing when it could change the next option.
Are immunotherapy side effects permanent?
Some immune-related effects improve with treatment, while others can persist or appear after treatment ends. Report symptoms promptly and follow the medicine-specific monitoring plan.
What should I do if I develop a new symptom?
Use the oncology team’s instructions. Ask before treatment which symptoms require a same-day call or emergency care and who is available after hours; do not assume a symptom is minor because the treatment is called targeted or immunotherapy.
What if my test is negative or inconclusive?
The result may make one biomarker-dependent option less likely, but it does not automatically eliminate every treatment. The team should review sample quality, assay limits, other evidence-based options, and clinical trials.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallThe Bottom Line
Targeted therapy acts on a cancer-related target or signal, while immunotherapy activates, redirects, or supplies immune activity against cancer. Some treatments overlap, and both categories can have serious, treatment-specific risks. Biomarker testing can identify possibilities but cannot promise benefit. Compare the actual medicine, its evidence, monitoring, and alternatives with your oncology team.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
